Emerging peptide therapies are disrupting the landscape of metabolic disease treatment. Among these groundbreaking advancements, semaglutide and tirzepatide stand out as potent agents with remarkable therapeutic potential. These glucagon-like peptide-1 (GLP-1) receptor agonists possess unique mechanisms of action that combat multiple facets of meta